FDA Rejects Edsivo NDA for Vascular Ehlers-Danlos Syndrome
In the CRL, the FDA stated that the Company will need to conduct an adequate and well-controlled trial to evaluate the efficacy of Edsivo in patients with vEDS.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
